Trial · NCT07902024
Xuanbai Yiqi Decoction for Sepsis: A Randomized Controlled Trial
NCT07902024, Not applicable, Not yet recruiting, Shanghai Jiao Tong University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Xuanbai Yiqi Decoction for Sepsis: A Randomized Controlled Trial. Trials, record NCT07902024. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902024
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Xuanbai Yiqi Decoction for Sepsis: A Randomized Controlled Trial
- NCT number
- NCT07902024
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 280 participants, estimated
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
- Conditions
- Sepsis
- Interventions
- Xuanbai Chengqi Decoction, Xuanbai Chengqi Decoction; Forest-Cultivated Ginseng, Xuanbai Yiqi Decoction, Inactive Chinese Herbal Decoction Placebo
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes47
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in SOFA score from baseline to Day 7 | From baseline (before the first dose) to Day 7 | The Sequential Organ Failure Assessment (SOFA) score is a measure of organ dysfunction (range 0-24, with higher scores indicating more severe dysfunction). The primary endpoint is the improvement between the four groups, defined as baseline SOFA score minus Day 7 SOFA score. SOFA score is assessed at baseline (before the first dose) and on Day 7. |
| Secondary | All-cause mortality at 28 days | 28 days | All-cause mortality at 28 days after enrollment. |
| Secondary | Duration of intensive care unit (ICU) stay | From enrollment to ICU discharge (assessed up to Day 28) | Duration of ICU stay, calculated from ICU admission to ICU discharge using medical records and reported in days. |
| Secondary | Duration of total hospital stay | From enrollment to hospital discharge (assessed up to Day 28) | Total hospital length of stay, calculated from hospital admission to hospital discharge using medical records and reported in days. |
| Secondary | Change in prothrombin time (PT) from baseline to Day 28 | Days 1, 3, 5, 7, 14, 21, and 28 | PT will be measured in plasma using an automated coagulation analyzer and reported in seconds. |
| Secondary | Change in activated partial thromboplastin time (APTT) from baseline to Day 28 | Days 1, 3, 5, 7, 14, 21, and 28 | APTT will be measured in plasma using an automated coagulation analyzer and reported in seconds. |
| Secondary | Change in international normalized ratio (INR) from baseline to Day 28 | Days 1, 3, 5, 7, 14, 21, and 28 | INR will be calculated from prothrombin time using an automated coagulation analyzer and reported as a dimensionless ratio. |
| Secondary | Change in fibrinogen concentration from baseline to Day 28 | Days 1, 3, 5, 7, 14, 21, and 28 | Fibrinogen concentration will be measured in plasma using an automated coagulation analyzer and reported in g/L. |
| Secondary | Change in D-dimer concentration from baseline to Day 28 | Days 1, 3, 5, 7, 14, 21, and 28 | D-dimer concentration will be measured in plasma using an immunoassay and reported in mg/L fibrinogen-equivalent units (FEU). |
| Secondary | Change in platelet count from baseline to Day 28 | Days 1, 3, 5, 7, 14, 21, and 28 | Platelet count will be measured in whole blood using an automated hematology analyzer and reported as ×10⁹/L. |
1 to 10 of 47Source ClinicalTrials.gov
See all 47 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902024
GET https://conductscience.org/api/trials/v1/NCT07902024/registered?page=2